GDNF and Parkinson disease: One patient from the initial pilot study demonstrated persistent clinical and 18F-DOPA PET improvement despite cessation of GDNF infusion for 3 years [81], suggesting that heterogeneity in patient responses, similar to that seen in PD transplantation studies, may also play a part in the negative outcome in the multi-centre study.